全文获取类型
收费全文 | 35158篇 |
免费 | 3627篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 207篇 |
儿科学 | 1135篇 |
妇产科学 | 967篇 |
基础医学 | 4921篇 |
口腔科学 | 707篇 |
临床医学 | 4187篇 |
内科学 | 6373篇 |
皮肤病学 | 545篇 |
神经病学 | 3027篇 |
特种医学 | 1717篇 |
外国民族医学 | 3篇 |
外科学 | 4419篇 |
综合类 | 768篇 |
一般理论 | 43篇 |
预防医学 | 4254篇 |
眼科学 | 884篇 |
药学 | 2611篇 |
中国医学 | 46篇 |
肿瘤学 | 2016篇 |
出版年
2022年 | 270篇 |
2021年 | 617篇 |
2020年 | 327篇 |
2019年 | 572篇 |
2018年 | 604篇 |
2017年 | 463篇 |
2016年 | 512篇 |
2015年 | 548篇 |
2014年 | 762篇 |
2013年 | 1137篇 |
2012年 | 1630篇 |
2011年 | 1599篇 |
2010年 | 943篇 |
2009年 | 850篇 |
2008年 | 1452篇 |
2007年 | 1550篇 |
2006年 | 1535篇 |
2005年 | 1470篇 |
2004年 | 1433篇 |
2003年 | 1342篇 |
2002年 | 1278篇 |
2001年 | 1192篇 |
2000年 | 1205篇 |
1999年 | 1039篇 |
1998年 | 462篇 |
1997年 | 414篇 |
1996年 | 409篇 |
1995年 | 340篇 |
1994年 | 361篇 |
1993年 | 358篇 |
1992年 | 822篇 |
1991年 | 790篇 |
1990年 | 777篇 |
1989年 | 697篇 |
1988年 | 724篇 |
1987年 | 674篇 |
1986年 | 620篇 |
1985年 | 694篇 |
1984年 | 554篇 |
1983年 | 439篇 |
1982年 | 290篇 |
1981年 | 304篇 |
1980年 | 265篇 |
1979年 | 465篇 |
1978年 | 348篇 |
1977年 | 282篇 |
1976年 | 288篇 |
1975年 | 267篇 |
1974年 | 285篇 |
1972年 | 268篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation—Efficacy and Safety at Five Years 总被引:2,自引:0,他引:2
Christopher J. E. Watson J. Andrew Bradley Peter J. Friend John Firth Craig J. Taylor John R. Bradley Kenneth G. C. Smith Sathia Thiru Neville V. Jamieson Geoff Hale Herman Waldmann Roy Calne 《American journal of transplantation》2005,5(6):1347-1353
Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on day 0 and 1, followed by half-dose cyclosporin monotherapy (trough concentration 75-125 ng/mL) from day 3. They were compared in a retrospective contemporaneous-controlled manner with 66 kidney transplant recipients transplanted in the same period and center who received conventional immunosuppression with cyclosporin, azathioprine and prednisolone. In the alemtuzumab group 12% of recipients died compared to 17% in the control group (p = 0.48); likewise graft loss was similar in both groups (21% vs. 26%, respectively, p = 0.58). Incidence of acute rejection was also comparable at 5 years (31.5% vs. 33.6%), although the pattern of rejection was different with 14% patients in the alemtuzumab group experiencing rejection over 1 year post-transplant compared to none in the control group. There was no significant difference between groups in terms of infection or serious adverse events. While acknowledging the limitations of a relatively small single-center study, results suggest that alemtuzumab induction allowed satisfactory long-term patient and graft survival equivalent to that seen with standard triple immunosuppression, while avoiding steroid therapy. 相似文献
33.
T L Taylor 《Clinics in Podiatric Medicine and Surgery》1989,6(3):537-553
In summary, factors to consider in treatment are (1) the patient's age; (2) the flexibility of the condition; (3) the severity of deformity; (4) the presence of equinus; (5) abnormal shoe wear; and (6) the symptoms. When a child presents with severe flexible flatfoot one should rule out an underlying neuromuscular disorder and perform a complete biomechanical evaluation to ascertain any rotational or angular conditions of the legs that might influence the treatment. If a child is in group 1 (ages 4 to 7), a Helfet heel seat with a medial plantar wedge is usually adequate treatment. In the group II (ages 8 to 12) adolescent with flexible flatfoot, more control of the calcaneal eversion is needed. This is obtained by using a device constructed from a plaster mold taken while the foot is in neutral position. This UCBL type of device must usually extend to the metatarsal heads and be elevated on the medial and lateral sides. The group III (ages 13 to 17) adolescent usually has the additional problem of a forefoot varus, which must be controlled using a forefoot post. It is also not unusual to have to add additional wedging inside the heel of the shoe to invert the heel. 相似文献
34.
35.
Taylor Moran-Gates Christopher Grady Young Shik Park Ross J Baldessarini Frank I Tarazi 《European neuropsychopharmacology》2007,17(6-7):448-455
The atypical antipsychotic risperidone is often prescribed to pediatric patients with neuropsychiatric disorders, though its effects on the developing brain remain unclear. Accordingly, we studied the effects of repeated treatment of risperidone on dopamine receptors in brain regions of juvenile rat. Levels of dopamine receptors (D(1), D(2), D(3), D(4)) in forebrain regions of juvenile rats were quantified after 3 weeks of treatment with three different doses of risperidone (0.3, 1.0 and 3.0 mg/kg) and compared findings to those in adult rats treated with risperidone (3.0 mg/kg/day) previously. Risperidone (at 1.0 and 3.0 mg/kg/day) increased levels of D(1) receptors in nucleus accumbens and caudate-putamen of juvenile, but not adult rats. Conversely, all three doses of risperidone dose-dependently increased D(2) labeling in medial prefrontal cortex and hippocampus, and D(4) receptor in nucleus accumbens, caudate-putamen and hippocampus of juvenile animals as well as in adults. Only the high dose of risperidone (3.0 mg/kg) increased D(2) receptors in caudate-putamen in both juvenile and adult brain. D(3) receptors were not altered by risperidone in any brain region at any dose or age. The findings indicate dose-dependent effects of risperidone on dopamine receptors in developing animals, and that juvenile animals are more sensitive than adults to the cerebral effects of risperidone. 相似文献
36.
37.
Anticoagulant drugs are known to have an effect on tumour growth. However, the mechanisms by which they act are poorly understood, and have therefore been investigated in this study. Wistar rats were given eight weekly subcutaneous injections of azoxymethane, at a dose of 10 mg kg-1 week-1. Following this they were randomized into two groups: a control group, which received no further treatment, and a warfarin treated group, which received warfarin at 'non-therapeutic' doses in their drinking water, for a further 8 weeks. Pairs of rats from each group were killed at 5-weekly intervals from 10 to 35 weeks after the first azoxymethane injection. At 40 weeks all remaining rats were killed. Samples of colonic mucosa from the descending colon and rectum were taken for scanning electron microscopy. The number of microadenomas per low power field was determined in both groups at each time interval. Tumour incidence and distribution were noted in animals killed at 40 weeks. The median number of microadenomas was significantly lower in warfarin treated animals than in controls at all time intervals. Tumour number was also significantly decreased by warfarin treatment (27 in azoxymethane treated animals, 10 in animals receiving azoxymethane and warfarin, P less than 0.05). The distribution of tumours along the colon was similar to that seen previously, following 12 weeks of azoxymethane. These effects occurred despite the non-concurrent administration of azoxymethane and warfarin. 相似文献
38.
Hua Tan Jena Derrick Jin Hong Corneliu Sanda William M Grosse Howard J Edenberg Milton Taylor Scott Seiwert Lawrence M Blatt 《Journal of interferon & cytokine research》2005,25(10):632-649
A role for type II interferon (IFN-gamma) in resolving viral infection is suggested by the correlation of hepatitis C virus (HCV) clearance with enhancement of IFN-gamma-producing activated T cells in the resolution of acute HCV infection. Using vesicular stomatitis virus (VSV), a synergistic direct antiviral effect was documented using IFN-gamma1b and a potent, consensus type I IFN (IFN alfacon-1). Global expression profiling following EC50 exposure to IFN alfacon-1, IFN-gamma1b, or a cocktail of the two allowed the antiviral state to be correlated with induction of a subset of IFN-stimulated genes (ISGs). Genes identified through this analysis corresponded to classic antiviral components, ISGs more recently associated with direct antiviral functions, as well as expressed sequence tags (ESTs) and hypothetical proteins. The magnitude of these antiviral EC50-correlated expression events in human hepatoma (Huh7) cells exposed to clinically relevant doses of IFN alfacon-1, IFN-gamma1b, or a cocktail of the two was also probed because the standard of care for patients with chronic hepatitis C is type I IFN-containing regimens. Relative to type I IFNs used alone, the addition of type II IFN caused enhanced expression not only of many of the genes correlated with the direct antiviral state but also of genes involved in (1) antigen presentation to cytotoxic T lymphocytes (CTLs), (2) macrophage, natural killer (NK), and T helper 1 (Th1) cell recruitment and activation, (3) complement system function, (4) apoptosis, and (5) ISGs with unknown functions. As many of these processes are correlated clinically with resolution of chronic HCV infection, the combined use of these IFNs could display a beneficial effect on viral clearance in patients infected with HCV and other viruses through enhancement of one of these processes or of the direct antiviral state. 相似文献
39.
Israel Liberzon Stephan F Taylor K Luan Phan Jennifer C Britton Lorraine M Fig Joshua A Bueller Robert A Koeppe Jon-Kar Zubieta 《Neuropsychopharmacology》2007,61(9):1030-1038
BACKGROUND: Functional neuroimaging studies have detected abnormal limbic and paralimbic activation to emotional probes in posttraumatic stress disorder (PTSD), but few studies have examined neurochemical mechanisms that underlie functional alterations in regional cerebral blood flow. The mu-opioid neurotransmitter system, implicated in responses to stress and suppression of pain, is distributed in and is thought to regulate the function of brain regions that are implicated in affective processing. METHODS: Here we examined the micro-opioid system with positron emission tomography and the micro-opioid receptor-selective radiotracer [11C] carfentanil in 16 male patients with PTSD and two non-PTSD male control groups, with (n = 14) and without combat exposure (n = 15). Differences in micro-opioid receptor binding potential (BP2) were detected within discrete limbic and paralimbic regions. RESULTS: Relative to healthy controls, both trauma-exposed groups had lower micro-opioid receptor BP2 in extended amygdala, nucleus accumbens, and dorsal frontal and insular cortex but had higher BP2 in the orbitofrontal cortex. PTSD patients exhibited reduced BP2 in anterior cingulate cortex compared with both control groups. Micro-opioid receptor BP2 in combat-exposed subjects without PTSD was lower in the amygdala but higher in the orbitofrontal cortex compared with both PTSD patients and healthy controls. CONCLUSIONS: These findings differentiate the general response of the micro-opioid system to trauma from more specific changes associated with PTSD. 相似文献
40.